Cns Drugs

Journal Title：Cns Drugs

CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes:

- Overviews of contentious or emerging issues.

- Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses.

- Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

- Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry.

- Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

CNS Drugs 致力于促進臨床精神病學和神經病學學科內的合理藥物治療。該期刊包括：

- 有爭議或新興問題的概述。

- 全面的敘述性評論，提供有關治療神經和精神疾病的藥理學方法的權威信息來源。

- 系統評價，使用 PRISMA 聲明概述的明確、系統方法，匯總經驗證據以回答特定的研究問題。

- Adis 藥物評論，介紹神經病學和精神病學中新藥和成熟藥物的特性和治療地位。

- 原創研究文章，報告精心設計的研究結果，與臨床實踐密切相關，例如臨床藥效學和藥代動力學研究、臨床試驗、薈萃分析、結果研究以及藥物經濟學和藥物流行病學研究。

其他數字功能（包括動畫摘要、視頻摘要、幻燈片、音頻幻燈片、教學視頻、信息圖表、播客和動畫（英語：Animals）可以與文章一起發表；這些旨在提高期刊內容的可見性、讀者群和教育價值。此外，在 CNS Drugs 上發表的文章可能會附有通俗易懂的摘要，以幫助對該領域有一定了解但不具備深入專業知識的讀者了解重要的醫學進展。

Cns Drugs創刊于1994年，由Springer International Publishing出版商出版，收稿方向涵蓋醫學 - 精神病學全領域，此刊是該細分領域中屬于非常不錯的SCI期刊，在行業細分領域中學術影響力較大，專業度認可很高，所以對原創文章要求創新性較高，如果您的文章質量很高，可以嘗試。平均審稿速度 較慢,6-12周 ，影響因子指數7.4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。